CYTK CYTOKINETICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%
Returns
ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $47.56M | $28.62M | $19.36M | $17.75M | $1.94M | $66.77M | $1.58M | $16.93M |
| R&D expense | $99.28M | $97.81M | $95.53M | $104.40M | $97.30M | $110.14M | $98.26M | $93.63M |
| SG&A expense | $113.14M | $104.40M | $104.90M | $91.72M | $69.46M | $65.72M | $57.37M | $62.34M |
| Operating income | -$167.09M | -$179.17M | -$183.62M | -$178.37M | -$166.75M | -$111.51M | -$155.63M | -$139.04M |
| Interest expense | — | — | — | $14.27M | $11.35M | $11.08M | — | $8.94M |
| Net income | -$190.07M | -$198.76M | -$206.03M | -$183.03M | -$306.18M | -$134.37M | -$161.38M | -$150.02M |
| EBITDA | -$163.44M | -$175.54M | -$180.24M | -$175.50M | -$164.08M | -$109.22M | -$153.33M | -$136.66M |
| EPS (basic) | -1.37 | -1.50 | -1.67 | — | -2.55 | -1.12 | -1.36 | — |
| EPS (diluted) | -1.37 | -1.50 | -1.67 | — | -2.55 | -1.12 | -1.36 | — |
| Weighted avg. shares (diluted) | 139,045 | 132,086 | 123,273 | — | 119,982 | 119,457 | 118,496 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $203.43M | $255.27M | $129.84M | $122.52M | $225.47M | $74.94M | $73.68M | $94.86M |
| Short-term investments | $926.59M | $910.41M | $688.71M | $759.70M | $737.07M | $783.20M | $864.54M | $981.16M |
| Receivables | $33.89M | $24.43M | $6.83M | $17.76M | $1.81M | $8.41M | $2.01M | $16.65M |
| Inventory | $807,000 | $380,000 | $154,000 | $0 | — | — | — | — |
| Current assets | $1.19B | $1.21B | $839.47M | $916.98M | $977.35M | $886.54M | $956.05M | $1.11B |
| PP&E, net | $76.12M | $78.92M | $82.44M | $79.19M | $76.00M | $70.22M | $67.17M | $65.81M |
| Total assets | $1.82B | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B |
| Current liabilities | $353.42M | $181.43M | $199.19M | $202.45M | $142.14M | $131.06M | $159.73M | $179.67M |
| Short-term debt | $174.40M | $27.36M | $44.81M | $41.18M | $17.28M | $14.40M | $12.96M | $11.52M |
| Long-term debt | $244.33M | $248.20M | $247.21M | $246.38M | $158.75M | $159.06M | $92.03M | $93.23M |
| Total debt | $418.73M | $275.56M | $292.02M | $287.56M | $176.03M | $173.46M | $104.98M | $104.75M |
| Total liabilities | $2.15B | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B |
| Shareholders' equity | -$321.17M | -$173.49M | -$826.57M | -$659.62M | -$521.12M | -$368.72M | -$266.41M | -$135.37M |
| Net debt | $215.30M | $20.29M | $162.17M | $165.05M | -$49.44M | $98.52M | $31.30M | $9.89M |
| Shares outstanding | — | — | — | 122.94M | — | — | — | 118.21M |
| Cash flow statement | ||||||||
| Operating cash flow | -$124.02M | -$159.84M | -$145.46M | -$142.65M | -$107.50M | -$128.24M | -$131.62M | -$65.57M |
| Capital expenditure | $700,000 | $4.33M | $5.93M | $5.64M | $9.35M | $4.14M | $5.66M | $1.29M |
| Free cash flow | -$124.72M | -$164.17M | -$151.39M | -$148.29M | -$116.86M | -$132.38M | -$137.28M | -$66.86M |
| Investing cash flow | $67.93M | -$507.00M | $145.49M | -$71.19M | -$70.98M | $52.88M | $105.96M | $110.86M |
| Financing cash flow | $4.80M | $792.86M | $7.77M | $110.70M | $330.47M | $78.53M | $4.75M | $2.38M |
| Depreciation & amortization | $3.65M | $3.63M | $3.38M | $2.86M | $2.68M | $2.29M | $2.30M | $2.38M |
| Stock-based compensation | $34.72M | $35.71M | $30.39M | $30.51M | $30.70M | $27.54M | $23.55M | $26.25M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.